Navigation Links
URAC Director of Pharmacy Programs to Speak at Academy of Managed Care Pharmacy Annual Meeting
Date:4/16/2009

To Provide Overview of Pharmacy Benefit Management Accreditation Standards

WASHINGTON, April 16 /PRNewswire-USNewswire/ -- URAC, the leading health care accreditation and education organization, announced today that Director of Pharmacy Programs Janice Anderson, RPh, has been selected to speak at the 21st Annual Academy of Managed Care Pharmacy (AMCP) Meeting, the largest assembly of pharmacy and health care professionals dedicated solely to the issues of managed care pharmacy. Ms. Anderson will discuss in importance of accreditation for Pharmacy Benefit Management (PBM) programs and provide insider tips on navigating the accreditation process.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO)

"Since the launch of our PBM accreditation program, we have received strong interest in the standards and we are pleased to find that organizations are dedicated to doing what is right for the consumer. These standards assure companies that they are receiving the highest quality products and services from health plans and PBM organizations," Ms. Anderson said. "We are honored to be part of the AMCP annual meeting. It is a great opportunity to discuss the value of accreditation with leading health care professionals and pharmacy benefit management companies so they can become more efficient and instill more confidence in the consumers they serve."

Since the implementa
'/>"/>

SOURCE URAC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sinobiopharma, Inc. Appoints New Director of Marketing
2. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
3. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
4. Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders
5. Trusted LASIK Surgeons Welcomes LASIK Expert William Mathers, M.D. of the Casey Vision Correction Center in Portland, Oregon, to Its LASIK Directory
6. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
7. Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVFs Stockholder-Oriented Nominees
8. Oxygen Biotherapeutics, Inc. Expands Board of Directors
9. Syndication Inc. Seeks DIRECTOR OF TECHNICAL ENGINEERING for PINNACLE ENERGY - Its New Alternative Energy Subsidiary
10. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors
11. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 2Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 3Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 4Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 5Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 6Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 7Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 8Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 9Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 10Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 11Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 12Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 13Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 14Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 15Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 16Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 17Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 18Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 19Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 20Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 21Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 22Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 23Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 24Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 25Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 26Boston Scientific Announces Results for Third Quarter Ended September 30, 2008 27Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 2Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 3Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 4Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 5Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 6Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 7Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 8Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 9Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares. 10